Donaldson L.Chief medical officer annual report on the state of the public health. London: Department of Health , 2001.
2.
Jones EA.Hepatocellular failure. In Weatherall DJ , Ledingham JGG , Worrell DA eds. Oxford textbook medicine, third edition. New York: Oxford University Press , 1996.
3.
McIntyre N , Burroughs AK.Cirrhosis, portal hypertension and ascites. In Weatherall DJ , Ledingham JGG , Worrell DA eds. Oxford textbook medicine, third edition. New York: Oxford University Press , 1996.
4.
Riordan S , Williams R.Treatment of hepatic encephalopathy . N Engl J Med1997; 337: 473-479 .
Remington H , Swallow R , Daly MJ , Bramley P.Drug choice in patients with liver disease . Pharm J1992; 248: 845-848 .
7.
Seeff LB.Acetaminophen hepatotoxicity in alcoholics . Ann Int Med1986; 104: 399-404 .
8.
Kotb HI , El-Kabsh Y , Emara S , Fouad E.Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis . Br J Anaesth1997; 79: 804-806 .
9.
Tegeder I , Lotsche J , Geisslinger G.Pharmacokinetics of opioids in liver disease . Clin Pharmacokinet1999; 37: 17-40 .
10.
Hasselstrom J , Eriksson S , Persson A , Rane A , Svensson JO , Sawe J.The metabolism and bioavailability of morphine in patients with severe liver cirrhosis . Br J Clin Pharmacol1990; 29: 289-297 .
11.
Tallgren M , Olkkola K , Seppala T , Hockerstedt K , Lindgren L.Pharmacokinetics and ventilatory effects of oxycodone before and after transplantation . Clin Pharmacol Ther1997; 61: 655-661 .
12.
Westphal JF , Brogard JM.Drug administration in chronic liver disease . Drug Saf1997; 17: 47-73 .
13.
Danzinger LH , Martin SJ , Blum RA.Central nervous system toxicity associated with meperidine use in hepatic disease . Pharmacotherapy1994; 14: 235-238 .
14.
Liver disease and drug disposition . Br J Anaesthesia. 1992; 68: 459-461 .
15.
Prabhaker S , Bhatia R.Management of agitation and convulsions in hepatic encephalopathy . Indian J Gastroenterol2003; 22: S54-S58 .